This comprehensive volume offers an in-depth exploration of dermatologic therapeutics, encompassing both foundational principles and the latest advancements in the field. Each drug is presented with a clear and concise overview, covering its introduction, mechanism of action, pharmacokinetics, indications, contraindications, clinical applications, adverse effects, and considerations for use during pregnancy, lactation, and in geriatric and pediatric populations.
Designed as an essential resource for clinicians, researchers, and students, the book provides a thorough understanding of both systemic and topical therapies in dermatology. Besides, it features detailed discussions on retinoids, biological immunomodulators and immunosuppressive agents—core components of modern dermatologic treatment. Enhanced with numerous flow diagrams and tables the book effectively illustrates key concepts and therapeutic pathways, offering readers a clear and structured perspective on clinical decision-making in dermatology. This is volume 1 of the set of three volumes.
Section I Antimicrobial drugs.- Chapter 1 Penicillins.
Chapter 2
Cefalosporins.
Chapter 3 Quinolones.
Chapter 4 Macrolides.
Chapter 5
Tetracyclines.
Chapter 6 Clindamycin.
Chapter 7 Metronidazole.
Chapter
8 Rifampicin.
Chapter 9 Vancomycin.
Chapter 10 Newer antimicrobials.-
Section II Antiviral drugs.
Chapter 11 Acyclovir and Valacyclovir.-
Chapter 12 Famciclovir.
Chapter 13 Cidofovir.
Chapter 14 Foscarnet.-
Section III Antifungal drugs.
Chapter 15 Azoles.
Chapter 16
Terbenafine.
Chapter 17 Griseofulvin.
Chapter 18 Amphotericin B.-
Chapter 19 5-Flucytosine.
Chapter 20 Echinocandins.
Chapter 21
Nikkomycin Z.- Section IV Systemic steroids.
Chapter 22 Systemic
glucocorticorticoids.
Chapter 23 Steroid pulses in dermatology.- Section V
Immunosuppressive drugs.
Chapter 24 Cyclophosphamide.
Chapter 25
Cyclosporine.
Chapter 26 Methotrexate.
Chapter 27 Azathioprine.
Chapter
28 Mycophenolate mofetil.
Chapter 29 Hydroxyurea.- Section VI Oral
retinoids.
Chapter 30 Isotretinoin.
Chapter 31 Acitretin.
Chapter 32
Alitretinoin.
Chapter 33 Bexarotene.- Section VII Biologic
immunomodulators.
Chapter 34 TNF alpha antagonists.
Chapter 35
Ustekinumab.
Chapter 36 IL-17 antagonists.
Chapter 37 IL-23
antagonists.
Chapter 38 Dupilumab.
Chapter 39 Omalizumab.
Chapter 40
Rituximab.
Chapter 41 Anakinra.
Dr. Aditya Kumar Bubna is a Dermatologist, currently working as an Associate Professor in the Department of Dermatology, Katihar Medical College, Katihar, India. He has more than 50 publications in national and international journals. His particular interest is dermatologic therapeutics, with a keen interest on various pharmacologic and therapeutic aspects of dermatologic drugs, both topical and systemic. He feels that a thorough knowledge in this regard assists in the introduction of innovative strategies, that can significantly aid in reducing the frequency of conventional drug administration, thereby helping in alleviating the prevalence of side effects. He further percieves that safety and efficacy of drugs go hand in hand, when it comes to treating patients, and a thorough knowledge of these drugs therefore becomes essential for all clinicians. His other interest in this field includes dermatopathology, an indispensable facet of diagnostic dermatology.
